Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11014735 | 1.00 | BACE1 (0.54) | BACE1ELANETSHRMDM4MDM2 | |
| SCHEMBL9575337 | 0.91 | ELANE (0.57) | ELANETACR1MMP8GAATP53 | |
| SCHEMBL6715971 | 0.86 | PPARG (0.63) | MMP8GAAALDH1A1PPARG | |
| SCHEMBL21428974 | 0.84 | CTSG (0.52) | ELANETACR1MMP8TP53ALDH1A1 | |
| SCHEMBL28699378 | 0.83 | BACE1 (0.54) | BACE1ELANETSHRMDM4MDM2 | |
| SCHEMBL6936961 | 0.83 | MMP8 (0.54) | BACE1TSHRMDM4MDM2MMP8 | |
| SCHEMBL18351661 | 0.82 | PPARG (0.56) | PPARG | |
| SCHEMBL3923892 | 0.82 | PPARG (0.56) | PPARG | |
| SCHEMBL3923887 | 0.82 | PPARG (0.56) | PPARG | |
| Hydrochloric Acid SCHEMBL27445685 | 0.82 | TACR1 (0.52) | TACR1PPARGCTSLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-0916651-B1 | PHENYLALKYLCARBOXYLIC ACID DERIVATIVES | SANKYO CO (JP) | 2003-10-15 | — | — | EP | disclosed |
| CN-1104413-C | Phenylalkylcarboxylic acid derivatives | SANKYO CO (JP) | 2003-04-02 | — | — | CN | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| CN-1280561-A | Amidocarboxylic acid derivatives | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| US-6103907-A | ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT | SANKYO COMPANY, LIMITED (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
| CN-1219927-A | Phenylalkylcarboxylic acid derivatives | SANKYO CO (JP) | 1999-06-16 | — | — | CN | disclosed |
| EP-0916651-A1 | PHENYLALKYLCARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | BACE1 4375/4885ELANE 915/4885TSHR 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.